Current and Future Anti-Fibrotic Therapies for Chronic Liver Disease

Clinics in Liver Disease

Volumn 12, Issue 4, 2008, Pages 939-962

  Rockey, Don C ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Cirrhosis; Complication; Extracellular matrix; Fibrosis; Liver biopsy; Myofibroblast; Portal hypertension; Stellate cell

Indexed keywords

ALPHA INTERFERON; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ANTIVIRUS AGENT; BETA INTERFERON; CANDESARTAN; COLCHICINE; ETANERCEPT; GAMMA INTERFERON; GAMMA1B INTERFERON; GLYCYRRHIZIC ACID; INTERLEUKIN 1BETA; IRBESARTAN; IRON; LAMIVUDINE; LOSARTAN; MALOTILATE; METHOTREXATE; PEGINTERFERON ALPHA; PIOGLITAZONE; PIRFENIDONE; PLACEBO; POTASSIUM MAGNESIUM ASPARTATE; PREDNISONE; PROPRANOLOL DERIVATIVE; PROPYLTHIOURACIL; RIBAVIRIN; ROSIGLITAZONE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

ALCOHOL LIVER DISEASE; ANTIVIRAL THERAPY; AUTOIMMUNE HEPATITIS; BILE DUCT OBSTRUCTION; CLINICAL TRIAL; DECOMPRESSION SURGERY; DRUG MECHANISM; DRUG SAFETY; FIBROGENESIS; FIBROSING ALVEOLITIS; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS C; HUMAN; IRON DEPLETION; LIVER CIRRHOSIS; LIVER FIBROSIS; LOW CALORY DIET; MONOTHERAPY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIMARY BILIARY CIRRHOSIS; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WOUND HEALING;

ANGIOTENSIN II; CHRONIC DISEASE; COLCHICINE; COLLAGEN; EXTRACELLULAR MATRIX; HEPATIC STELLATE CELLS; HUMANS; INTERFERON-GAMMA; LIGANDS; LIVER CIRRHOSIS; PPAR GAMMA; PYRIDONES;

EID: 54549119172     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2008.07.011     Document Type: Review

References (179)

1. Caligiuri A., Glaser S., Rodgers R.E., et al. Endothelin-1 inhibits secretin-stimulated ductal secretion by interacting with ETA receptors on large cholangiocytes. Am J Physiol 275 (1998) G835-G846
2. Jarnagin W.R., Rockey D.C., Koteliansky V.E., et al. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 127 (1994) 2037-2048
3. Kinnman N., Francoz C., Barbu V., et al. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest 83 (2003) 163-173
4. Kisseleva T., Uchinami H., Feirt N., et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 45 (2006) 429-438
5. Russo F.P., Alison M.R., Bigger B.W., et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 130 (2006) 1807-1821
6. Wang X., Kanel G.C., and DeLeve L.D. Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat. Hepatology 31 (2000) 428-434
7. Wells R.G., Kruglov E., and Dranoff J.A. Autocrine release of TGF-beta by portal fibroblasts regulates cell growth. FEBS Lett 559 (2004) 107-110
8. Zeisberg M., Yang C., Martino M., et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 282 (2007) 23337-23347
9. Maher J.J., and McGuire R.F. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest 86 (1990) 1641-1648
10. Rockey D.C., Boyles J.K., Gabbiani G., et al. Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. J Submicrosc Cytol Pathol 24 (1992) 193-203
11. Arthur M.J. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 279 (2000) G245-G249
12. Benyon R.C., Iredale J.P., Goddard S., et al. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 110 (1996) 821-831
13. Emonard H., and Grimaud J.A. Active and latent collagenase activity during reversal of hepatic fibrosis in murine schistosomiasis. Hepatology 10 (1989) 77-83
14. Friedman S.L., Rockey D.C., and Bissell D.M. Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference. Hepatology 45 (2007) 242-249
15. Preaux A.M., Mallat A., Van Nhieu J.T., et al. Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions. Hepatology 30 (1999) 944-950
16. Takahara T., Furui K., Funaki J., et al. Increased expression of matrix metalloproteinase-II in experimental liver fibrosis in rats. Hepatology 21 (1995) 787-795
17. Garcia-Banuelos J., Siller-Lopez F., Miranda A., et al. Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion. Gene Ther 9 (2002) 127-134
18. Siller-Lopez F., Sandoval A., Salgado S., et al. Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology 126 (2004) 1122-1133 discussion 949
19. Issa R., Williams E., Trim N., et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 48 (2001) 548-557
20. Wright M.C., Issa R., Smart D.E., et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 121 (2001) 685-698
21. Zhang S., Ji G., and Liu J. Reversal of chemical-induced liver fibrosis in Wistar rats by puerarin. J Nutr Biochem 17 (2006) 485-491
22. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348 (2003) 800-807
23. Lai C.L., Chien R.N., Leung N.W., et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. [see comments]. N Engl J Med 339 (1998) 61-68
24. Mallet V.O., Dhalluin-Venier V., Verkarre V., et al. Reversibility of cirrhosis in HIV/HBV coinfection. Antivir Ther 12 (2007) 279-283
25. Abergel A., Darcha C., Chevallier M., et al. Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis. Eur J Gastroenterol Hepatol 16 (2004) 1219-1227
26. Poynard T., McHutchison J., Manns M., et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122 (2002) 1303-1313
27. Dufour J.F., DeLellis R., and Kaplan M.M. Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med 127 (1997) 981-985
28. Ramond M.J., Poynard T., Rueff B., et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 326 (1992) 507-512
29. Spahr L., Rubbia-Brandt L., Pugin J., et al. Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. J Hepatol 35 (2001) 582-589
30. Blumberg R.S., Chopra S., Ibrahim R., et al. Primary hepatocellular carcinoma in idiopathic hemochromatosis after reversal of cirrhosis. Gastroenterology 95 (1988) 1399-1402
31. Powell L.W., and Kerr J.F. Reversal of "cirrhosis" in idiopathic haemochromatosis following long-term intensive venesection therapy. Australas Ann Med 19 (1970) 54-57
32. Wu S.F., Peng C.T., Wu K.H., et al. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. Hemoglobin 30 (2006) 215-218
33. Hammel P., Couvelard A., O'Toole D., et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 344 (2001) 418-423
34. Neuschwander-Tetri B.A., Brunt E.M., Wehmeier K.R., et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38 (2003) 1008-1017
35. Blasco A., Forns X., Carrion J.A., et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 43 (2006) 492-499
36. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006) 865-873
37. Dienstag J.L., and McHutchison J.G. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 130 (2006) 231-264 quiz 214-7
38. Strader D.B., Wright T., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 39 (2004) 1147-1171
39. Rockey D.C., and Chung J.J. Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. J Clin Invest 98 (1996) 1381-1388
40. Bedossa P., Dargere D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38 (2003) 1449-1457
41. O'Brien M.J., Keating N.M., Elderiny S., et al. An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. Am J Clin Pathol 114 (2000) 712-718
42. Pilette C., Rousselet M.C., Bedossa P., et al. Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol 28 (1998) 439-446
43. Thampanitchawong P., and Piratvisuth T. Liver biopsy: complications and risk factors. World J Gastroenterol 5 (1999) 301-304
44. Ratziu V., Charlotte F., Heurtier A., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128 (2005) 1898-1906
45. Regev A., Berho M., Jeffers L.J., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 97 (2002) 2614-2618
46. Rockey D.C., and Bissell D.M. Noninvasive measures of liver fibrosis. Hepatology 43 (2006) S113-S120
47. Poynard T., Bedossa P., and Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349 (1997) 825-832
48. Wai C.T., Greenson J.K., Fontana R.J., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 38 (2003) 518-526
49. Colli A., Fraquelli M., Andreoletti M., et al. Severe liver fibrosis or cirrhosis: accuracy of US for detection-analysis of 300 cases. Radiology 227 (2003) 89-94
50. Imbert-Bismut F., Ratziu V., Pieroni L., et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 357 (2001) 1069-1075
51. Callewaert N., Van Vlierberghe H., Van Hecke A., et al. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 10 (2004) 429-434
52. McHutchison J.G., Blatt L.M., de Medina M., et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 15 (2000) 945-951
53. Rockey D.C. Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography. Gastroenterology 134 (2008) 8-14
54. Sandrin L., Fourquet B., Hasquenoph J.M., et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29 (2003) 1705-1713
55. Castera L., Foucher J., Bertet J., et al. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. Hepatology 43 (2006) 373-374 author reply 375-6
56. Fraquelli M., Rigamonti C., Casazza G., et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 56 (2007) 968-973
57. Ziol M., Handra-Luca A., Kettaneh A., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 41 (2005) 48-54
58. Bataller R., Gabele E., Parsons C.J., et al. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology 41 (2005) 1046-1055
59. Bataller R., Sancho-Bru P., Gines P., et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology 125 (2003) 117-125
60. Hirose A., Ono M., Saibara T., et al. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. Hepatology 45 (2007) 1375-1381
61. Jin H., Yamamoto N., Uchida K., et al. Telmisartan prevents hepatic fibrosis and enzyme-altered lesions in liver cirrhosis rat induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 364 (2007) 801-807
62. Nabeshima Y., Tazuma S., Kanno K., et al. Anti-fibrogenic function of angiotensin II type 2 receptor in CCl4-induced liver fibrosis. Biochem Biophys Res Commun 346 (2006) 658-664
63. Rockey D.C. Vascular mediators in the injured liver. Hepatology 37 (2003) 4-12
64. De B.K., Bandyopadhyay K., Das T.K., et al. Portal pressure response to losartan compared with propranolol in patients with cirrhosis. Am J Gastroenterol 98 (2003) 1371-1376
65. Debernardi-Venon W., Martini S., Biasi F., et al. AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers. J Hepatol 46 (2007) 1026-1033
66. Gonzalez-Abraldes J., Albillos A., Banares R., et al. Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. Gastroenterology 121 (2001) 382-388
67. Schepke M., Werner E., Biecker E., et al. Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterology 121 (2001) 389-395
68. Tripathi D., Therapondos G., Lui H.F., et al. Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis. Am J Gastroenterol 99 (2004) 390-394
69. Czaja M.J., Weiner F.R., Eghbali M., et al. Differential effects of gamma-interferon on collagen and fibronectin gene expression. J Biol Chem 262 (1987) 13348-13351
70. Rockey D.C., and Chung J.J. Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J Investig Med 42 (1994) 660-670
71. Rockey D.C., Maher J.J., Jarnagin W.R., et al. Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma. Hepatology 16 (1992) 776-784
72. Muir A.J., Sylvestre P.B., and Rockey D.C. Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. J Viral Hepat 13 (2006) 322-328
73. Pockros P.J., Jeffers L., Afdhal N., et al. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis. Hepatology 45 (2007) 569-578
74. Weng H.L., Wang B.E., Jia J.D., et al. Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study. Clin Gastroenterol Hepatol 3 (2005) 819-828
75. Chevallier M., Guerret S., Chossegros P., et al. A histological semiquantitative scoring system for evaluation of hepatic C fibrosis in needle liver biopsy specimens: comparison with morphometric C studies. Hepatology 20 (1994) 349-355
76. Knodell R.G., Ishak K.G., Black W.C., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1 (1981) 431-435
77. Miyahara T., Schrum L., Rippe R., et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 275 (2000) 35715-35722
78. Hazra S., Xiong S., Wang J., et al. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells. J Biol Chem 279 (2004) 11392-11401
79. Yang L., Chan C.C., Kwon O.S., et al. Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 291 (2006) G902-G911
80. Lutchman G., Modi A., Kleiner D.E., et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 46 (2007) 424-429
81. Belfort R., Harrison S.A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006) 2297-2307
82. Di Sario A., Bendia E., Macarri G., et al. The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. Dig Liver Dis 36 (2004) 744-751
83. Di Sario A., Bendia E., Svegliati Baroni G., et al. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol 37 (2002) 584-591
84. Garcia L., Hernandez I., Sandoval A., et al. Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol 37 (2002) 797-805
85. Liu H., Drew P., Gaugler A.C., et al. Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway. Am J Transplant 5 (2005) 1256-1263
86. Shimizu T., Kuroda T., Hata S., et al. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 54 (1998) 99-109
87. Tada S., Nakamuta M., Enjoji M., et al. Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin Exp Pharmacol Physiol 28 (2001) 522-527
88. Azuma A., Nukiwa T., Tsuboi E., et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171 (2005) 1040-1047
89. Armendariz-Borunda J., Islas-Carbajal M.C., Meza-Garcia E., et al. A pilot study in patients with established advanced liver fibrosis using pirfenidone. Gut 55 (2006) 1663-1665
90. Poo J.L., Feldmann G., Moreau A., et al. Early colchicine administration reduces hepatic fibrosis and portal hypertension in rats with bile duct ligation. J Hepatol 19 (1993) 90-94
91. Rodriguez L., Cerbon-Ambriz J., and Munoz M.L. Effects of colchicine and colchiceine in a biochemical model of liver injury and fibrosis. Arch Med Res 29 (1998) 109-116
92. Rojkind M., and Kershenobich D. Effect of colchicine on collagen, albumin and transferrin synthesis by cirrhotic rat liver slices. Biochim Biophys Acta 378 (1975) 415-423
93. Kaplan M.M., Alling D.W., Zimmerman H.J., et al. A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 315 (1986) 1448-1454
94. Kershenobich D., Vargas F., Garcia-Tsao G., et al. Colchicine in the treatment of cirrhosis of the liver. N Engl J Med 318 (1988) 1709-1713
95. Morgan T.R., Nemchausky B., Schiff E.R., et al. Colchicine does not prolong life in patients with advanced alcoholic cirrhosis: results of a prospective, randomized, placebo-controlled trial. Gastroenterology (2002) 641A
96. Rambaldi A., and Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis or cirrhosis. Liver 21 (2001) 129-136
97. Miller L.C., Sharma A., McKusick A.F., et al. Synthesis of interleukin-1 beta in primary biliary cirrhosis: relationship to treatment with methotrexate or colchicine and disease progression. Hepatology 22 (1995) 518-524
98. Nikolaidis N., Kountouras J., Giouleme O., et al. Colchicine treatment of liver fibrosis. Hepatogastroenterology 53 (2006) 281-285
99. Angelico M., Cepparulo M., Barlattani A., et al. Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C. Aliment Pharmacol Ther 14 (2000) 1459-1467
100. Douglas W.W., Ryu J.H., Swensen S.J., et al. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study. Members of the Lung Study Group. Am J Respir Crit Care Med 158 (1998) 220-225
101. Selman M., Carrillo G., Salas J., et al. Colchicine, D-penicillamine, and prednisone in the treatment of idiopathic pulmonary fibrosis: a controlled clinical trial. Chest 114 (1998) 507-512
102. Mandal A.K., Das S., Basu M.K., et al. Hepatoprotective activity of liposomal flavonoid against arsenite-induced liver fibrosis. J Pharmacol Exp Ther 320 (2007) 994-1001
103. Sakaida I., Tsuchiya M., Kawaguchi K., et al. Herbal medicine Inchin-ko-to (TJ-135) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J Hepatol 38 (2003) 762-769
104. Shimizu I., Ma Y.R., Mizobuchi Y., et al. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. [see comments]. Hepatology 29 (1999) 149-160
105. Zhang X.L., Liu L., and Jiang H.Q. Salvia miltiorrhiza monomer IH764-3 induces hepatic stellate cell apoptosis via caspase-3 activation. World J Gastroenterol 8 (2002) 515-519
106. Luk J.M., Wang X., Liu P., et al. Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. Liver Int 27 (2007) 879-890
107. Wang B.E. Treatment of chronic liver diseases with traditional Chinese medicine. J Gastroenterol Hepatol 15 15 (2000) E67-E70
108. Stedman C. Herbal hepatotoxicity. Semin Liver Dis 22 (2002) 195-206
109. Boigk G., Stroedter L., Herbst H., et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26 (1997) 643-649
110. Jia J.D., Bauer M., Cho J.J., et al. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J Hepatol 35 (2001) 392-398
111. Lieber C.S., Leo M.A., Cao Q., et al. Silymarin retards the progression of alcohol-induced hepatic fibrosis in baboons. J Clin Gastroenterol 37 (2003) 336-339
112. Ferenci P., Dragosics B., Dittrich H., et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 9 (1989) 105-113
113. Pares A., Planas R., Torres M., et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. [see comments]. J Hepatol 28 (1998) 615-621
114. Aleynik S.I., Leo M.A., Ma X., et al. Polyenylphosphatidylcholine prevents carbon tetrachloride-induced lipid peroxidation while it attenuates liver fibrosis. J Hepatol 27 (1997) 554-561
115. Lieber C.S., Weiss D.G., Groszmann R., et al. II. Veterans Affairs Cooperative Study of Polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res 27 (2003) 1765-1772
116. Nava-Ocampo A.A., Suster S., and Muriel P. Effect of colchiceine and ursodeoxycholic acid on hepatocyte and erythrocyte membranes and liver histology in experimentally induced carbon tetrachloride cirrhosis in rats. Eur J Clin Invest 27 (1997) 77-84
117. Combes B., Carithers Jr. R.L., Maddrey W.C., et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 22 (1995) 759-766
118. Degott C., Zafrani E.S., Callard P., et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 29 (1999) 1007-1012
119. Goulis J., Leandro G., and Burroughs A.K. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 354 (1999) 1053-1060
120. Jacquemin E., Hermans D., Myara A., et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 25 (1997) 519-523
121. Lindblad A., Glaumann H., and Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 27 (1998) 166-174
122. Lindor K.D., Kowdley K.V., Heathcote E.J., et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 39 (2004) 770-778
123. Poupon R.E., Bonnand A.M., Chretien Y., et al. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology 29 (1999) 1668-1671
124. Poupon R.E., Lindor K.D., Pares A., et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 39 (2003) 12-16
125. Stiehl A. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis. Ann Med 26 (1994) 345-349
126. Thompson K., Maltby J., Fallowfield J., et al. Interleukin-10 expression and function in experimental murine liver inflammation and fibrosis. [see comments]. Hepatology 28 (1998) 1597-1606
127. Nelson D.R., Tu Z., Soldevila-Pico C., et al. Long-term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 38 (2003) 859-868
128. Albano E. Oxidative mechanisms in the pathogenesis of alcoholic liver disease. Mol Aspects Med 29 (2008) 9-16
129. Brown K.E., Poulos J.E., Li L., et al. Effect of vitamin E supplementation on hepatic fibrogenesis in chronic dietary iron overload. Am J Physiol 272 (1997) G116-G123
130. Hasegawa T., Yoneda M., Nakamura K., et al. Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 15 (2001) 1667-1672
131. Houglum K., Venkataramani A., Lyche K., et al. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology 113 (1997) 1069-1073
132. Mezey E., Potter J., Rennie-Tankersley L., et al. A randomized placebo controlled trial of vitamin E in alcoholic hepatitis. Hepatology 38 (2003) 264A
133. Stewart S., Prince M., Bassendine M., et al. A trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 36 S (2002) 16
134. Anonymous. The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group. J Hepatol 17 (1993) 227-235
135. Rambaldi A., and Gluud C. Meta-analysis of propylthiouracil for alcoholic liver disease-a Cochrane Hepato-Biliary Group Review. Liver 21 (2001) 398-404
136. Bodenheimer Jr. H.C., Schaffner F., Sternlieb I., et al. A prospective clinical trial of D-penicillamine in the treatment of primary biliary cirrhosis. Hepatology 5 (1985) 1139-1142
137. Dickson E.R., Fleming T.R., Wiesner R.H., et al. Trial of penicillamine in advanced primary biliary cirrhosis. N Engl J Med 312 (1985) 1011-1015
138. Schaff Z., Lapis K., Szende B., et al. The effect of D-penicillamine on CCl4-induced experimental liver cirrhosis. Exp Pathol 43 (1991) 111-120
139. Lu S.C., Tsukamoto H., and Mato J.M. Role of abnormal methionine metabolism in alcoholic liver injury. Alcohol 27 (2002) 155-162
140. Mato J.M., Camara J., Fernandez de Paz J., et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 30 (1999) 1081-1089
141. Aithal G.P., Haugk B., Das S., et al. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified?. Aliment Pharmacol Ther 19 (2004) 391-399
142. Nohlgard C., Rubio C.A., Kock Y., et al. Liver fibrosis quantified by image analysis in methotrexate-treated patients with psoriasis. J Am Acad Dermatol 28 (1993) 40-45
143. Te H.S., Schiano T.D., Kuan S.F., et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 95 (2000) 3150-3156
144. Bach N., Bodian C., Bodenheimer H., et al. Methotrexate therapy for primary biliary cirrhosis. Am J Gastroenterol 98 (2003) 187-193
145. Bach N., Thung S.N., and Schaffner F. The histologic effects of low-dose methotrexate therapy for primary biliary cirrhosis. Arch Pathol Lab Med 122 (1998) 342-345
146. Hendrickse M.T., Rigney E., Giaffer M.H., et al. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. [see comments]. Gastroenterology 117 (1999) 400-407
147. Kaplan M.M., DeLellis R.A., and Wolfe H.J. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med 126 (1997) 682-688
148. Kaplan M.M., Cheng S., Price L.L., et al. A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. Hepatology 39 (2004) 915-923
149. Bahcecioglu I.H., Koca S.S., Poyrazoglu O.K., et al. Hepatoprotective effect of Infliximab, an anti-TNF-alpha agent, on carbon tetrachloride-induced hepatic fibrosis. Inflammation 31 (2008) 215-221
150. Koca S.S., Bahcecioglu I.H., Poyrazoglu O.K., et al. The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet. Inflammation 31 (2008) 91-98
151. Akriviadis E., Botla R., Briggs W., et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 119 (2000) 1637-1648
152. Menon K.V., Stadheim L., Kamath P.S., et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 99 (2004) 255-425
153. Spahr L., Rubbia-Brandt L., Frossard J.L., et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 37 (2002) 448-455
154. Tilg H., Jalan R., Kaser A., et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 38 (2003) 419-425
155. Boetticher N.C., Piene C.J., Kwo P., et al. Gastroenterology 134 (2008) A765
156. George J., Roulot D., Koteliansky V.E., et al. In vivo inhibition of rat stellate cell activation by soluble TGF beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Nat Acad Sci U S A 96 (1999) 12719-12724
157. Isaka Y., Brees D.K., Ikegaya K., et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 2 (1996) 418-423
158. Yata Y., Gotwals P., Koteliansky V., et al. Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy. Hepatology 35 (2002) 1022-1030
159. Siegmund S.V., and Schwabe R.F. Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am J Physiol Gastrointest Liver Physiol 294 (2008) G357-G362
160. Hezode C., Roudot-Thoraval F., Nguyen S., et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 42 (2005) 63-71
161. Julien B., Grenard P., Teixeira-Clerc F., et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 128 (2005) 742-755
162. Teixeira-Clerc F., Julien B., Grenard P., et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 12 (2006) 671-676
163. Corpechot C., Barbu V., Wendum D., et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 35 (2002) 1010-1021
164. Tugues S., Fernandez-Varo G., Munoz-Luque J., et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 46 (2007) 1919-1926
165. Buck M., and Chojkier M. A ribosomal S-6 Kinase-mediated signal to C/EBP-beta is critical for the development of liver fibrosis. PLoS ONE 2 (2007) e1372
166. Khimji A.K., Shao R., and Rockey D.C. Divergent transforming growth factor-beta signaling in hepatic stellate cells after liver injury: functional effects on ECE-1 regulation. Am J Pathol 173 (2008) 716-727
167. Beljaars L., Molema G., Schuppan D., et al. Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. J Biol Chem 275 (2000) 12743-12751
168. Douglass A., Wallace K., Parr R., et al. Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury. J Hepatol 49 (2008) 88-98
169. Du S.L., Pan H., Lu W.Y., et al. Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J Pharmacol Exp Ther 322 (2007) 560-568
170. Gonzalo T., Beljaars L., van de Bovenkamp M., et al. Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells. J Pharmacol Exp Ther 321 (2007) 856-865
171. Hagens W.I., Beljaars L., Mann D.A., et al. Cellular targeting of the apoptosis-inducing compound gliotoxin to fibrotic rat livers. J Pharmacol Exp Ther 324 (2008) 902-910
172. Luk J.M., Zhang Q.S., Lee N.P., et al. Hepatic stellate cell-targeted delivery of M6P-HSA-glycyrrhetinic acid attenuates hepatic fibrogenesis in a bile duct ligation rat model. Liver Int 27 (2007) 548-557
173. Akinc A., Zumbuehl A., Goldberg M., et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 26 (2008) 561-569
174. Sato Y., Murase K., Kato J., et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol 26 (2008) 431-442
175. Wolfrum C., Shi S., Jayaprakash K.N., et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25 (2007) 1149-1157
176. van Rooij E., Sutherland L.B., Qi X., et al. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316 (2007) 575-579
177. Fiorucci S., Antonelli E., Rizzo G., et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127 (2004) 1497-1512
178. Liu Y., Binz J., Numerick M.J., et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest 112 (2003) 1678-1687
179. Rockey D.C. Antifibrotic therapy in chronic liver disease. Clin Gastroenterol Hepatol 3 (2005) 95-107